Business Context and Reporting Period
Company: Cryolife, Inc. (Note: Request metadata listed "Artivion, Inc.", but the filing text identifies the registrant as Cryolife, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1998
Business Overview: Cryolife provides cryopreservation services for human tissues (heart valves, vascular tissue, connective tissue) and manufactures single-use medical devices and bioprosthetic cardiovascular devices. The company acquired Ideas for Medicine, Inc. ("IFM") in March 1997, expanding its product line.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Total Revenues | $14,625,000 | $10,413,000 |
| Net Income | $1,172,000 | $952,000 |
| Earnings Per Share (Diluted) | $0.12 | $0.10 |
| Gross Margin (Approx.) | 63% | 67% |
| Operating Cash Flow | $698,000 | ($2,259,000) |
| Net Working Capital | $59.5 million | $18.8 million (Dec 31, 1997) |
| Current Ratio | 9:1 | N/A |
| Total Debt (Long-term + Current) | $18.9 million (Proforma) | $17.4 million |
Note: Gross margin calculated as (Revenues - Cost of Cryopreservation and Products) / Revenues. Proforma debt figures reflect the repayment of bank loans using proceeds from a follow-on equity offering.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 40% to $14.6 million, driven by a 15% increase in heart valve shipments, a 37% increase in vascular tissue shipments, and a 158% surge in knee connective tissue shipments.
- Margin Compression: Cost of cryopreservation services rose 60% (from 33% to 37% of revenue). This was attributed to higher manufacturing overhead from a new facility and the inclusion of three months of lower-margin IFM sales compared to one month in the prior year.
- Expense Increases: General, administrative, and marketing expenses rose 30% to $5.8 million due to revenue support costs and European market expansion for BioGlue. Interest expense increased to $430,000 due to full-quarter interest on convertible debentures and bank loans.
- Cash Flow Improvement: Operating cash flow turned positive ($698,000) compared to a $2.3 million outflow in Q1 1997, primarily due to reduced liquidation of accounts payable.
Guidance, Outlook, and Risks
- Capital Raise: In April 1998, the company completed a follow-on equity offering of approximately 3 million shares, netting $45.45 million. Proceeds were used to repay $13.3 million in bank loans and interest, with the remainder for expansion and working capital.
- Liquidity: Management anticipates that proceeds from the offering and operating cash flow will meet needs for the next 12 months. Future liquidity depends on FDA approvals for products in development.
- Seasonality: Demand for heart valve and conduit services peaks in Q2 and Q3. Knee tissue services may be seasonal due to elective procedure timing.
- Risks: Key risks include government regulation, competitive position, tissue availability, product development status, and third-party reimbursement rates. The company also noted potential Year 2000 compliance issues for vendors, though internal systems are compliant.
Investor Verification Checklist
- Debt Repayment Confirmation: Verify the actual repayment of the $13.3 million in bank loans using the April 1998 equity proceeds as reflected in the proforma balance sheet.
- IFM Integration: Assess the long-term impact of the IFM acquisition on gross margins, as the lower-margin device sales are diluting overall profitability.
- Seasonal Trends: Monitor Q2 and Q3 results to confirm the anticipated peak demand for heart valve services.
- Regulatory Status: Track the timeline for FDA approvals for the company's bioadhesives and synergraft technologies, which are critical for future growth.
- Capital Expenditures: Review the utilization of remaining equity proceeds for the expansion of manufacturing facilities.